Skip to main content
SMFM 2025 Pregnancy Meeting Main banner
Final Program


Program Book
Icon Legend
Presentation Icons
Additional registration fee required
Additional registration fee required
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Recording
Recording
Poster Icons
Additional registration fee required
Additional registration fee required
Faculty have requested this content not be shared on social media
Faculty have requested this content not be shared on social media
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Back

Poster Session 1

(249) Association of maternal serum 25-Hydroxyvitamin D level in mid-gestation with fetal adiposity: a longitudinal study

Thursday, January 30, 2025
10:30 AM – 12:30 PM  
Objective: 25-Hydroxyvitamin D (25(OH)D) regulates lipid metabolism, and its decrease is proposed as a pathogenesis of metabolic syndrome. Fetuses are dependent on supply of 25(OH)D from maternal circulation though pregnant women are described as a population at risk for decreased 25(OH)D. Recently, quantitative evaluation of fetal adiposity using ultrasonography has been established, and clinical investigations revealed that gestational diabetes mellitus (GDM) is associated with increased fetal adiposity. However, the influence of maternal serum 25(OH)D on fetal fat deposition remains unclear. This study aimed to investigate the association of maternal serum 25(OH)D level in mid-gestation with fetal adiposity.

Study Design: A prospective study was conducted in a cohort of 89 (including 22 GDM) singleton pregnancies. Maternal blood sample was obtained at 24 weeks. Fetal ultrasonography was performed serially at 24, 30 and 36 weeks. Estimated fetal adiposity (EFA) was calculated by integrating measurements of cross-sectional arm and thigh percentage fat area and anterior abdominal wall thickness as previously reported. The association between maternal serum 25(OH)D and EFA were determined by multiple linear regression adjusted for potential covariates including maternal age, parity, pre-pregnancy BMI, gestational weight gain and fetal sex. GDM was diagnosed by the national clinical practice guideline based on the 75g oral glucose tolerance test.

Results: Maternal serum 25(OH)D at 24 weeks was 16.2±7.7 ng/ml (mean±S.D.). Maternal serum 25(OH)D was not associated with EFA at 24 and 30 weeks, but significantly and inversely correlated with EFA at 36 weeks (r = -0.223, p = 0.032). The magnitude of this association was pronounced particularly in GDM group (r = -0.447, p = 0.033), and not significant in non-GDM group (r = -0.147, p = 0.227).

Conclusion: Maternal serum 25(OH)D level in mid-gestation was inversely associated with fetal adiposity in late gestation. Maternal 25(OH)D could be an early biomarker of fetal adiposity especially in the diabetic pregnancies.